Paul Joseph Kleindl

This inventor holds 9 USPTO granted patents and 12 published patent applications and 2 EPO patents. Top assignee: Endocyte, Inc.. Active years: 2014-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Joseph Kleindl. Retrieved from https://idiyas.com/inventor/paul-joseph-kleindl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 12)

% Patents Active = 22.2

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 36(Granted Patents)

Company Filing History:

9 out of 60

Endocyte, Inc.

patents

Years Active: 2014-2020

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10857234 - Carbonic anhydrase IX inhibitor conjugates and uses thereof (2020-12-08),

2. 10738086 - Conjugates containing hydrophilic spacer linkers (2020-08-11),

3. 10500204 - Vitamin receptor drug delivery conjugates for treating inflammation (2019-12-10),

4. 9877965 - Vitamin receptor drug delivery conjugates for treating inflammation (2018-01-30),

5. 9505747 - Processes for preparing tubulysin derivatives and conjugates thereof (2016-11-29),

6. 9499849 - Processes for preparing tubulysins (2016-11-22),

7. 9273091 - Processes for preparing tubulysins (2016-03-01),

8. 9138484 - Conjugates containing hydrophilic spacer linkers (2015-09-22),

9. 8889880 - Processes for preparing tubulysins (2014-11-18),

Title: **Inventor Spotlight: Paul Joseph Kleindl**

Introduction

Paul Joseph Kleindl, a notable inventor based in Lebanon, Indiana, has made significant contributions to the field of pharmaceuticals with a focus on innovative therapeutic strategies. With a total of nine patents to his name, Kleindl’s work emphasizes the development of targeted drug delivery systems that have the potential to improve cancer therapy outcomes.

Latest Patents

Among Kleindl's most recent patents is the invention titled "Carbonic Anhydrase IX Inhibitor Conjugates and Uses Thereof." This patent pertains to compositions and methods involving carbonic anhydrase IX inhibitors, detailing how these conjugates can serve as effective therapeutics and imaging agents. Additionally, he has developed conjugates containing hydrophilic spacer linkers, which enhance targeted drug delivery through cell-surface receptor binding. This innovation addresses disease states caused by pathogenic cell populations, showcasing Kleindl's commitment to advancing treatment methodologies.

Career Highlights

Kleindl’s career is marked by his work at Endocyte, Inc., a company dedicated to developing targeted therapies for cancer. His expertise and inventive spirit have propelled advancements in precision medicine, particularly in the context of drug conjugates. His nine patents reflect a commitment to not only scientific exploration but also practical applications that can have real-world impacts on patient care.

Collaborations

Throughout his career, Kleindl has collaborated with esteemed colleagues, including Christopher Paul Leamon and Iontcho Radoslavov Vlahov. These partnerships underscore the collaborative nature of innovation in the field of pharmaceuticals, where sharing knowledge and expertise can lead to groundbreaking developments.

Conclusion

Paul Joseph Kleindl serves as an inspiring figure within the realm of pharmaceuticals and invention. His contributions through numerous patents and collaborative efforts demonstrate the importance of innovation in creating effective treatments for challenging diseases. As he continues to push the boundaries of what is possible in drug delivery and cancer therapy, his work remains vital to the future of medical advancements.

Profile summary based on public USPTO records.